The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
==== United Kingdom ==== In the United Kingdom, preparations containing only dextropropoxyphene were discontinued in 2004. In 2007, the Medicines and Healthcare products Regulatory Agency removed the licence for co-proxamol, also called distalgesic. From then on in the UK, co-proxamol is only available on a named patient basis, for long-term chronic pain and only to those who have already been prescribed this medicine. Its withdrawal from the UK market is a result of concerns relating to its toxicity in overdose (even small overdoses can be fatal), and dangerous reaction with alcohol. Recreational use in the UK is uncommon. Many patients have been prescribed alternative combinations of drugs as a replacement. The motivation for the withdrawal of co-proxamol was the reduction in suicides and a key part of the agency's justification of its decision was based upon studies showing co-proxamol was no more effective than paracetamol alone in pain management. The co-proxamol preparations available in the UK contained a subtherapeutic dose of paracetamol, 325 mg per tablet. Patients were warned not to take more than eight tablets in one day, a total dose of 2600 mg paracetamol per day. Despite this reduced level, patients were still at a high risk of overdose; coproxamol was second only to tricyclic antidepressants as the most common prescription drugs used in overdose. Following the reduction in prescribing in 2005–2007, prior to its complete withdrawal, the number of deaths associated with the drug dropped significantly.
In October 2010, Biden said Obama had asked him to remain as his running mate for the 2012 presidential election, but with Obama's popularity declining, White House Chief of Staff William M. Daley conducted some secret polling and focus group research in late 2011 on the idea of replacing Biden with Hillary Clinton. The notion was dropped when the results showed no appreciable improvement, and White House officials later said Obama himself never entertained the idea. Biden's May 2012 statement that he was "absolutely comfortable" with same-sex marriage gained considerable public attention in comparison to Obama's position, which had been described as "evolving". Biden made his statement without administration consent, and Obama and his aides were irked, since Obama had planned to shift position in the build-up to the party convention. Gay rights advocates seized upon Biden's statement, and within days, Obama announced that he too supported same-sex marriage, an action in part forced by Biden's remarks. Biden had a heavy schedule of appearances in swing states as the reelection campaign began in earnest in spring 2012. An August 2012 remark before a mixed-race audience that Republican proposals to relax Wall Street regulations would "put y'all back in chains" again drew attention to Biden's propensity for colorful remarks.
==== Luca Visentini ==== Visentini was detained on 9 December 2022 and released without charge two days later. In a statement issued through the ITUC, he replied to the allegations by proclaiming his innocence and "reconfirming his absolutely commit[ment] to the fight against corruption" He also commented specifically on his confession in relation to receiving two payments from the NGO Fight Impunity of €50,000 and €60,000 by stating the monies were in relation to his campaign to become the General-Secretary of ITUC and that "it was in no way connected to a corruption attempt or aimed at influencing my position on Qatar." In March 2023 he was dismissed as general-secretary of the ITUC.
== Anatomy == One carotid sheath is situated on each side of the neck, extending between the base of the skull superiorly and the thorax inferiorly. Superiorly, the carotid sheath encircles the margins of the carotid canal and jugular foramen. Inferiorly, it terminates at the arch of the aorta; it is continuous inferiorly with the axillary sheath at the venous angle. Its inferior end occurs at the level of the first rib and sternum inferiorly (varying between the levels of C7 and T4).
Sources: en.wikipedia.org
The Gateway Program is the planned expansion and renovation of the Northeast Corridor between Newark, New Jersey, and New York City to alleviate the bottleneck by allowing for refurbishment of the existing North River Tunnels and ultimately expanding the right-of-way to four tracks, doubling the capacity of Penn Station. Two new tunnels under the Hudson River would add 25 cross-Hudson train slots during rush hours. Some proposals anticipated a four-platform, seven-track expansion of Penn Station with a new annex to the south to take advantage of the new capacity, but current reconstruction plans envision increasing capacity through some limited through-running instead. The Gateway Program was unveiled in 2011, one year after the cancellation of the somewhat-similar Access to the Region's Core (ARC) project, and was originally projected to cost $13.5 billion and take 14 years to build. Construction of a "tunnel box" to preserve right-of-way on Manhattan's West Side began in September 2013. In 2015, Amtrak said that damage done to the existing trans-Hudson tunnels by Sandy had made their replacement urgent and reported that design work on the tunnel component was underway, estimating the project cost at $20 billion. A draft environmental impact statement on the Hudson Tunnel project was released in July 2017, but the first Trump administration delayed consideration of it. Unblocking the project was a stated priority of the Biden administration, and the project was approved in May 2021.
=== Redox biology and drug metabolism in disease and therapeutics === Townsend has made contributions to the field of biochemistry, particularly in the context of oxidative stress, redox regulation, and their implications in various diseases. Exploring the impact of oxidative stress and redox regulation on cellular differentiation, she investigated their role in diseases associated with abnormal cell differentiation. In a collaborative study with Tapiero and Tew, she provided details on carotenoids as dietary antioxidants, highlighting their role in preventing cancer and cardiovascular diseases by mitigating oxidative damage and promoting intercellular communication. She also identified S-glutathionylation as a cell stress indicator and unfolded protein response regulator, linking it to pathologies and potential therapies influenced by oxidative stress and endoplasmic reticulum redox conditions. In another joint study, her work delved into the role of cysteine S-glutathionylation in redox cell signaling, proposing it as a biomarker for oxidative/nitrosative stress and its utility for individuals exposed to stress-inducing agents affecting protein clusters. Townsend's research has discussed the multifaceted role of glutathione S-transferase P (GSTP) in mediating S-glutathionylation, negatively regulating kinase pathways, and contributing to cellular redox homeostasis, with implications for drug development.
Ubiquitin is a small protein that exists in all eukaryotic cells. It performs its myriad functions through conjugation to a large range of target proteins. A variety of different modifications can occur. The ubiquitin protein itself consists of 76 amino acids and has a molecular mass of about 8.6 kDa. Key features include its C-terminal tail and the 7 lysine residues. It is highly conserved throughout eukaryote evolution; human and yeast ubiquitin share 96% sequence identity. Moreover, human and yeast ubiquitin share two conserved salt bridges, K11–E34 and K27–D52, which are critical for protein stability and function.
From 1969 to 1971, Sanders resided in Montpelier. After moving to Burlington, he began his electoral political career as a member of the Liberty Union Party, a national umbrella party for various socialist-oriented state parties, originating in the anti-war movement and the People's Party. He ran as the Liberty Union candidate for governor of Vermont in 1972 and 1976 and as a candidate in the special election for U.S. senator in 1972 and in the general election in 1974. In the 1974 senatorial race, he finished third (5,901 votes; 4%), behind 34-year-old Chittenden County state's attorney Patrick Leahy (D; 70,629 votes; 49%) and two-term incumbent U.S. Representative Dick Mallary (R; 66,223 votes; 46%). In 1971, while researching an article for Liberty Union's newspaper Movement, Sanders stayed at Myrtle Hill Farm, a Vermont back to the land commune. He was asked to leave after three days for failing to contribute physical labor expected of all members. Some residents complained that Sanders spent his time engaging others in political discussions, distracting them from their work, with one member claiming the only way "any work was going to get accomplished" was if people were pulled out of Sanders's orbit. The 1976 campaign was the zenith of the Liberty Union's influence, with Sanders collecting 11,317 votes for governor and the party.
=== Identification of structural patterns === This method builds a library of known protein–protein interfaces from the PDB, where the interfaces are defined as pairs of polypeptide fragments that are below a threshold slightly larger than the Van der Waals radius of the atoms involved. The sequences in the library are then clustered based on structural alignment and redundant sequences are eliminated. The residues that have a high (generally >50%) level of frequency for a given position are considered hotspots. This library is then used to identify potential interactions between pairs of targets, providing that they have a known structure (i.e. present in the PDB).
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.